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OBJECTIVE: To conduct a cross-sectional study of trans-
gender men who had been pregnant and delivered after
transitioning from female-to-male gender to help guide
practice and further investigation.
MATERIALS AND METHODS: We administered a web-
based survey from March to December 2013 to inquire
about demographics, hormone use, fertility, pregnancy
experience, and birth outcomes. Participants were not
required to have been on hormone therapy to be
eligible. We used a mixed-methods approach to evaluate
the quantitative and qualitative data.
RESULTS: Forty-one self-described transgender men
completed the survey. Before pregnancy, 61% (n525)
had used testosterone. Mean age at conception was 28
years with a standard deviation of 6.8 years. Eighty-eight
percent of oocytes (n536) came from participants’ own
ovaries. Half of the participants received prenatal care
from a physician and 78% delivered in a hospital. Qual-
itative themes included low levels of health care provider
awareness and knowledge about the unique needs of
pregnant transgender men as well as a desire for resour-
ces to support transgender men through their pregnancy.
CONCLUSION: Transgender men are achieving preg-
nancy after having socially, medically, or both transi-
tioned. Themes from this study can be used to develop
transgender-appropriate services and interventions that
may improve the health and health care experiences of
transgender men.
(Obstet Gynecol 2014;0:1–8)
DOI: 10.1097/AOG.0000000000000540
Transgender individuals often report many barriersin attempting to access health care.1 The American
College of Obstetricians and Gynecologists (the
College) recently called on obstetrician–gynecologists
to help eliminate these barriers for transgender men
(also called female-to-male individuals) by creating
nondiscriminatory practices, assisting with gender
transition, and providing transgender-appropriate
and comprehensive health care.2 Despite the
College’s call to action, little systematic attention has
been paid to the health and reproductive experiences
of transgender men or those individuals who are born
with female sexual organs but who identify as male.
Transgender men are individuals who have a male
or masculine gender identity but were assigned female
at birth. The gender affirmation process may include
social, medical, and surgical aspects of transition,
although not all transgender men desire medical
intervention.3 Many transgender men desire children4
and there are anecdotal reports supporting the biolog-
ical possibility of pregnancy for transgender men who
retain a uterus and discontinue testosterone therapy.5–7
However, there is little scientific literature describing
pregnancy experiences among transgender men or
the effects of exogenous administration of testosterone
on fertility, pregnancy, and neonatal outcomes.8
Understanding transgender men’s experiences with
fertility, pregnancy, and birth will allow health care
providers to augment pre- and posttransition discus-
sions regarding fertility options, the roles of cross-sex
hormones on fecundity, potential birth outcomes, and
to support their physical and mental well-being during
pregnancy. Expanded knowledge may also help
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health care providers support transgender men in at-
taining and maintaining healthy pregnancies.
We conducted a mixed-methods study to explore
the experiences of transgender men and to contribute
to the knowledge base of fertility, conception, preg-
nancy experience, and birth outcomes among trans-
gender men.
MATERIALS AND METHODS
We conducted a cross-sectional survey from March to
December 2013 of transgender men (assigned female
at birth with a masculine, transmasculine, transmale,
or female-to-male gender identity) who had been
pregnant and delivered a neonate. Inclusion criteria
were: age older than 18 years, self-identification as
male before pregnancy, pregnancy within the last
10 years, and the ability to fill out the survey in
English. Eligibility criteria did not require any type of
medical (eg, testosterone use) or surgical (eg, bilateral
mastectomy) transition. We recruited study partici-
pants through convenience sampling and we collected
data using a web-based survey. Participation was not
limited by geographic location.
We administered the online survey through
REDCap,9 an encrypted and secure online survey
platform. The study contained 47 multiple-choice
questions and 24 questions addressing demographics,
hormone use, fertility, pregnancy experience, birth
experience, and fetal outcomes. The survey con-
cluded with four open-ended questions: “Is there
anything you would like medical providers to know
about transgender men and pregnancy?” “What was
the experience of being pregnant like for you?” “What
was the experience of giving birth like for you?”
“What was the postpartum experience like for you?”
The survey was developed by the authors in consul-
tation with the Center of Excellence for Transgender
Health at University of California, San Francisco and
other health care providers serving the transgender
community.
Initial recruitment occurred through distribution
to key stakeholders in lesbian, gay, bisexual, and
transgender health centers; transgender community
groups; and Internet-based social networking pages
created by study authors. We recruited additional
participants through initial contacts. We provided
interested individuals with a comprehensive study
description and links to the study. After accessing the
electronic study web site, participants were presented
with informed consent documents and participants
confirmed their consent through accessing a link to
web-based survey. No in-person contact was made
with survey participants.
We conducted a mixed-methods analysis to
evaluate the quantitative and qualitative data collected
from the survey. Using STATA 13.0, we performed
unadjusted analyses using x2 for method of delivery;
t tests for pregnancy age, body mass index, and ges-
tational age; and Fisher’s exact for all other variables
according to testosterone use before pregnancy. As
a result of nonresponse, variable totals may not sum
to column totals or within category totals. A P value of
#.05 was considered statistically significant. We ana-
lyzed the qualitative data using grounded theory,
identifying iterative themes, and adding new codes
as concepts emerged.10 This study was approved by
the University of California, San Francisco Commit-
tee on Human Research.
RESULTS
We excluded nine of the 56 participants who began
the survey as a result of insufficient responses for
analysis, and six others were excluded because they
did not meet study criteria indicating male gender
before pregnancy.11 We included participants who
identified as female or preferred “she” or “her” pro-
nouns only if they had more than one validating indi-
cator of a transgender identity (use of testosterone,
male identity with female pronouns, or female identity
with male pronouns). Forty-one participants remained
for final analysis (Table 1). Most of our participants
were from the western United States, identified as
white, and had completed at least some college. Pro-
noun preference differed between those who had used
testosterone and those who had not (P5.04). Partici-
pants who had previously used testosterone were
more likely to prefer the pronoun “he,” whereas those
who had not used testosterone were more likely to
identify with “they.” Although most respondents were
primiparous, those who had not used testosterone
were more likely to be multiparous (P5.006). Four
transgender men (10%), all of whom had been on
testosterone previously, reported a prior diagnosis of
polycystic ovary syndrome.
Twenty-five (61%) transgender men reported
using testosterone before pregnancy (Table 2).
Among those who had used testosterone, 20 (80%)
reported resuming menstruation within 6 months after
stopping testosterone. Five participants (20%) con-
ceived while still amenorrheic from testosterone use.
After pregnancy, six (38%) participants who had not
previously used testosterone before pregnancy initi-
ated use. Ten participants (40%) who had been on
previously testosterone reported that they had not
yet resumed testosterone use after pregnancy.
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Two thirds of pregnancies were planned (Table 3).
Before the most recent pregnancy, condoms were the
most common form of contraception followed by no
form of contraception and abstinence (defined as not
engaging in penile–vaginal intercourse). Those who
had previously used testosterone were more likely to
Table 1. Participant Characteristics
Characteristic All (N541)
Prior Testosterone Use
PYes (n525) No (n516)
Age (y)* 2866.8 2966.9 2766.8 .5
Gender identity† .07
Male 21 (51) 12 (48) 9 (56)
Transgender, female-to-male, transman 10 (24) 9 (36) 1 (6)
Bigender, gender fluid, genderqueer 8 (20) 3 (12) 5 (31)
Female 1 (2) 1 (4) 0
Other 1 (2) 0 1 (6)
Personal pronoun preference‡ .04
He 32 (82) 21 (88) 11 (73)
They 3 (8) 0 3 (20)
She 2 (5) 2 (8) 0
Ey 1 (2) 1 (4) 0
No pronouns 1 (2) 0 1 (7)
Country .4
United States 35 (85) 20 (80) 15 (94)
Outside United States§ 6 (15) 5 (20) 1 (6)
U.S. region‡k .9
West 19 (59) 11 (61) 8 (57)
Northeast 5 (16) 3 (17) 2 (14)
South 5 (16) 2 (11) 3 (21)
Midwest 3 (9) 2 (11) 1 (7)
Race or ethnicity‡ 1.0
White 36 (92) 21 (88) 15 (100)
Asian 1 (3) 1 (4) 0
Asian and black 1 (3) 1 (4) 0
Native Hawaiian or other Pacific Islander 1 (3) 1 (4) 0
Education level‡ .7
High school degree or less 4 (10) 3 (12.5) 1 (7)
Vocational training or some college 12 (31) 6 (25) 6 (40)
Associate or Bachelor’s degree 14 (36) 10 (42) 4 (27)
Master’s or doctoral degree 9 (23) 5 (21) 4 (27)
Annual household income ($)‡ .4
Less than 20,000 6 (15) 2 (8) 4 (25)
20,000–59,999 20 (49) 12 (50) 8 (50)
60,000–100,000 8 (20) 6 (25) 2 (13)
More than 100,000 5 (13) 4 (17) 1 (7)
Multiparous (2 or more pregnancies) 15 (37) 5 (20) 10 (63) .006
Previous PCOS diagnosis 4 (10) 4 (16) 0 .15
BMI at the start of pregnancy (kg/m2) 2666 2666 2766 .6
Gender-confirming surgical procedure‡¶ .7
Bilateral mastectomy 19 (46) 13 (52) 6 (38)
Oophorectomy 2 (5) 0 2 (13)
Hysterectomy 2 (5) 2 (8) 0
Phalloplasty or metoidioplasty# 1 (2) 1 (4) 0
PCOS, polycystic ovary syndrome/BMI, body mass index.
Data are mean6standard deviation or n (%) unless otherwise specified.
* Age at the beginning of their most recent pregnancy.
† Kuper et al.28
‡ Not all the participants answered this question.
§ Canada (n52), Germany (n51), England (n51), Israel (n51), and Switzerland (n51).
k Regions were defined according to the 2010 U.S. census.
¶ Surgery may have occurred before or after pregnancy.
# Metoidioplasty is procedure that separates the clitoris from the labia to assume a physiologic position similar to a penis (Djordjevic et al29).
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report no contraceptive use or abstinence, whereas
those who had not used testosterone were more likely
to use a hormonal contraceptive method (P5.03). The
majority of oocytes came from the participants’ own
ovaries, whereas the majority of sperm came from
a significant other or spouse. Most transgender men
became pregnant within 4 months of trying, only 15%
had a preconception medical consultation, and 7%
used fertility drugs to become pregnant.
Pregnancy, delivery, and birth outcomes did not
differ according to prior testosterone use (Table 4).
Half of the participants received prenatal care from
a physician, 40% from an obstetrician, and 10% from
a family medicine physician. More than three fourths
of the participants began taking prenatal vitamins
either before pregnancy or within the first trimester,
whereas 15% reported not taking any prenatal vita-
mins. Participants reported a variety of perinatal
complications including hypertension (12%), preterm
labor (10%), placental abruption (10%), and anemia
(7%). Anemia was not reported by participants who
had previously used testosterone. A higher proportion
of transgender men who had used testosterone under-
went cesarean delivery compared with those who
reported no testosterone use (36% compared with
19%, respectively), although this finding was not
statistically significant. Among those who underwent
a cesarean delivery, 25% cited the indication as
elective. Those who had previously used testosterone
were statistically less likely to chest (breast) feed their
infant than those who had not previously used testos-
terone (P5.04).
Thirty participants (73%) answered at least one of
the four open-ended questions. Major themes from
these responses were: 1) effect of pregnancy on
concepts of family structure; 2) isolation; 3) gender
dysphoria and pregnancy; and 4) interactions with
health care providers.
Many participants discussed their pregnancy in
the context of family structure. For some, pregnancy
was a necessary step in creating the family they
desired: “I looked at it as something to endure to have
a child” (36-year-old, prior testosterone use). Others
described the pregnancy in pragmatic terms, possibly
as a way to avoid gender dissonance: “Like my body
was a workshop, building up this little kid” (35-year-
old, prior testosterone use). Another participant found
a way to embrace the pregnancy, describing the preg-
nancy and birth as a bridge to fatherhood: “Pregnancy
and childbirth were very male experiences for me.
When I birthed my children, I was born into father-
hood” (29-year-old, no prior testosterone use). Partic-
ipants often used words such as “dad,” “carrier,” and
“gestational parent” to affirm their male gender iden-
tity and describe their parenting role.
Feelings of isolation were common. One partici-
pant stated, “Pregnancy came with feelings of isolation
and limitation” (28-year-old, prior testosterone use).
Some identified the source of isolation as stemming
from feeling “lonely because I was the only one”
(30-year-old, prior testosterone use). These feelings
were contextualized by comments about “lack of sup-
port” and “lack of resources available to pregnant
transgender men.” This isolation was also referenced
in terms of invisibility: “I passed as ‘not pregnant’
until my eighth month, because I’m chubby anyways,
and because people don’t assume that someone who
looks like me could be pregnant” (34-year-old, no
prior testosterone use). As another participant simply
put it: “We exist. And we are different” (35-year-old,
prior testosterone use).
Another theme that emerged was the relationship
between gender dysphoria and pregnancy. Some
participants reported improvements in gender dys-
phoria, feeling new connections with their bodies: “It
was relieving to feel comfortable in the body I’d been
born with” (20-year-old, no prior testosterone use).
Others felt an increase in dysphoria, and for some,
that dysphoria continued into the postpartum period:
“Heavy time, having a baby, not passing as male, all
the changes and a society telling me to just be happy”
Table 2. Findings Among Those Who Used
Testosterone Before Pregnancy of
Report (n525)
Characteristic Value
Age (y) when testosterone was initiated 25 (17–35)
Length of testosterone use before
pregnancy (y)
Less than 1 10 (40)
1–2 6 (24)
3–10 4 (16)
More than 10 5 (20)
Stopped taking testosterone to
become pregnant
17 (68)
Duration between stopping testosterone
and resumption of menses (mo)
No menses before pregnancy 5 (20)
Less than 1 2 (8)
1 6 (24)
2 7 (28)
3 4 (16)
4–6 1 (4)
Resumed or initiated testosterone
after pregnancy*
20 (48)
Data are median (range) or n (%).
* Of total respondents in the study (N541).
Copyright ª American College of Obstetricians and Gynecologists
4 Light et al Pregnancy Experiences of Transgender Men OBSTETRICS & GYNECOLOGY
(35-year-old, prior testosterone use). Combined with
feelings of isolation postpartum, many participants
specifically mentioned having postpartum depression.
“Began to show symptoms of postpartum depression
long before anyone discussed symptoms to watch
for. Began researching and working through post-
partum depression issues independently; found no
professional with familiarity with ‘trans/genderqueer’
gestational parents” (28-year-old, prior testosterone
use). As mentioned, the depression seemed amplified
by a lack of gender-sensitive resources for postpartum
depression.
In response to queries interactions with health
care providers, some participants mentioned positive
interactions with their health care teams regarding
their gender identity. “I was always called ‘he,’ I was
always called ‘dad,’ and my body parts were called by
the words I used” (34-year-old, prior testosterone use).
As previously, positive experiences often focused on
proper use of gender-related language. Other partic-
ipants mentioned negative experiences that ranged
from improper pronoun use and rude treatment to
being turned away from medical practices and denied
treatment. In one extreme experience, a participant
reported that “Child Protection Services was alerted
to the fact a ‘tranny’ had a baby” (21-year-old, prior
testosterone use). Many participants called for better
treatment from the health care system through
acknowledging the unique identities of pregnant trans-
gender men and grounding health care provider–
patient interactions in compassion and respect. As
one participant said, “treat us as if we are normal
human beings with normal bodies” (37-year-old, no
prior testosterone use). Additionally, participants
Table 3. Fertility Experiences Surrounding Most Recent Pregnancy by Prior Testosterone Use
Characteristic Total (N541)
Prior Testosterone Use
PYes (n525) No (n516)
Planned pregnancy 28 (68) 19 (76) 9 (56) .3
Contraception use before this pregnancy*† .03
Condoms 16 (41) 10 (40) 6 (43)
None 15 (38) 12 (48) 3 (21)
Abstinence‡ 3 (7) 3 (12) 0
Fertility awareness 2 (8) 0 2 (14)
Combined hormonal contraception (OCPs, transdermal patch,
vaginal ring)
1 (3) 0 1 (7)
Injection, intrauterine device, implant 1 (3) 0 1 (6)
Partner had vasectomy 1 (3) 0 1 (6)
Time to conception (mo)† .14
Unplanned pregnancy 13 (32) 6 (24) 7 (44)
Less than 1 3 (17) 1 (20) 2 (12)
1–3 9 (22) 8 (32) 1 (6)
4–6 8 (19) 5 (20) 3 (19)
More than 7 4 (10) 1 (4) 3 (18)
Source of oocyte .12
Own ovaries 36 (88) 21 (84) 15 (94)
Significant other or spouse 4 (10) 4 (16) 0
Anonymous donor 1 (2) 0 1 (6)
Source of sperm .5
Significant other, spouse, or romantic partner 31 (76) 17 (68) 14 (88)
Known donor 4 (10) 3 (12) 1 (6)
Anonymous donor or sperm bank 6 (15) 5 (20) 1 (6)
Medical intervention to become pregnant§
Consultation 6 (15) 4 (16) 2 (12)
Fertility drugs 3 (7) 2 (8) 1 (6)
Assisted reproductive technologyk 5 (12) 5 (20) 0
OCP, oral contraceptive pill.
Data are n (%) unless otherwise specified.
* Participants were given the option to identify with more than one, so total exceeds 100%.
† Not all the participants answered this question.
‡ Defined as not having penile–vaginal intercourse.
§ Participants could mark more than one, therefore not comparing the results statistically.
k Includes artificial insemination, in vitro fertilization, and gamete intrafallopian transfer.
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Table 4. Pregnancy Experience and Neonatal Outcomes
Characteristic Total (N541)
Prior Testosterone Use
PYes (n525) No (n516)
Source of prenatal care* 1.0
Obstetrician 16 (40) 9 (38) 7 (44)
Certified nurse midwife 11 (28) 7 (29) 4 (25)
Lay midwife 7 (18) 4 (17) 3 (19)
Family practice doctor 4 (10) 3 (13) 1 (6)
No prenatal care 2 (5) 1 (4) 1 (6)
Perinatal complications†
Hypertension 5 (12) 4 (16) 1 (6)
Preterm labor 4 (10) 3 (12) 1 (6)
Placental abruption 4 (10) 2 (8) 2 (12)
Anemia 3 (7) 0 3 (19)
Gestational diabetes 2 (5) 2 (8) 0
Multiple pregnancy‡ 2 (5) 2 (8) 0
Postpartum infection 2 (5) 1 (4) 1 (6)
Premature rupture of membranes 1 (2) 0 1 (6)
Pyelonephritis 1 (2) 1 (4) 0
Uterine rupture 1 (2) 1 (4) 0
Substance use§
Cigarettes 3 (7) 2 (8) 1 (6) 1.0
Alcohol 1 (2) 1 (4) 0 1.0
Recreational drugs 1 (2) 0 1 (6) .6
Gestational age at delivery (wk6d) 3866 3769 3965 .4
Location of birth .6
Hospital 32 (78) 18 (72) 14 (88)
Home 7 (17) 5 (20) 2 (13)
Independent birth center 2 (5) 2 (8) 0
Underwent labor induction 9 (22) 7 (28) 2 (12) .3
Method of delivery .5
Vaginal 29 (71) 16 (64) 13 (81)
Cesarean 12 (30) 9 (36) 3 (19)
Reason for cesarean delivery .6
Previous cesarean delivery 1 (8) 1 (11) 0
Breech presentation 1 (8) 1 (11) 0
Placenta previa 1 (8) 1 (11) 0
Arrest of labor 2 (17) 1 (11) 1 (33)
Multiple pregnancy (twins) 1 (8) 1 (11) 0
Requested cesarean delivery 3 (25) 3 (33) 0
Otherk 3 (25) 1 (11) 2 (66)
Birth weight (g)¶ 3,14661,671 2,91461,276 3,4906625 .2
Neonate admitted to the NICU* 5 (14) 4 (20) 1 (7) .4
Neonate diagnosed with an anomaly
or developmental disorder*#
3 (9) 1 (5) 2 (14) .7
Neonate diagnosed with a disorder
of sexual development***
2 (6) 1 (5) 1 (7) .8
Chest (breast) fed 21 (51) 10 (40) 11 (69) .04
NICU, neonatal intensive care unit.
Data are n (%) or mean6standard deviation unless otherwise specified.
* Not all the participants answered this question.
† Includes complications occurring in the preconception, antepartum, intrapartum, and postpartum periods.
‡ Both sets of multiples were twins.
§ Survey question stated: “Once you knew you were pregnant, did you regularly: _ drink alcohol, _ smoke cigarettes, _ use recreational
drugs, _ none of the above.”
k Other reasons for cesarean delivery: placental abruption (n51), preeclampsia (n51), none specified (n51).
¶ N542 neonates resulting from a set of twins.
# Ventricular septal defect (n51), bone cancer (n51), sensory integration disorder (n51).
** Intersex (n51), micropenis (n51).
Copyright ª American College of Obstetricians and Gynecologists
6 Light et al Pregnancy Experiences of Transgender Men OBSTETRICS & GYNECOLOGY
noted that although their specific health care provider(s)
may have been transgender-friendly, this was not
necessarily the case with the office staff, nurses, and
other health care workers.
DISCUSSION
The College has highlighted the need for obstetrician–
gynecologists to help eliminate barriers to care for
transgender men.2 Our results demonstrate that trans-
gender men desire children4 and are willing and able
to conceive, carry a pregnancy, and give birth. Partic-
ipants repeatedly expressed a desire for more infor-
mation regarding fertility options and access to
reproductive health care providers who respect,
support, and understand their gender identity.
Studies suggest that amenorrhea commonly
occurs within 6 months of initiating testosterone
therapy.12,13 However, timeframe for resumption of
menses after cessation of testosterone is unclear, and
some have stated amenorrhea may be irreversible.14
Participants who discontinued testosterone to attempt
pregnancy reported resumption of menses within 6
months, with the majority within 3 months. Some
conceived before return of menses. Despite small
sample size, the timeline for menses resumption is
consistent with that of literature on women who
became amenorrheic with Sertoli-Leydig tumors and
resumed menses after tumor resection.15
Although most transgender men in this study
received prenatal care from a physician and delivered
in a hospital, participants used nonphysician
providers and nonhospital birth locations more fre-
quently than the general public. In 2009, 99% of U.S.
births occurred in hospitals,16 compared with 78% of
our participants. It is possible that health care pro-
vider choice and delivery location were responses to
actual or anticipated negative experiences as sug-
gested from many qualitative reports of suboptimal
interactions with health care providers. However,
health care provider and birth location may have re-
sulted from other barriers such as access to health
insurance.17–20 Further research to clarify the experi-
ences of transgender men with peripartum service
provision will provide guidance for meeting their
needs.
There is a 12% prevalence of major depressive
disorders surrounding pregnancy, including postpar-
tum depression, for women in the United States.21
Although we did not specifically ask about depressive
disorders, many of our participants reported experi-
ences with peripartum depression in the narrative
responses. A Canadian study of mental health among
transgender men (n5207) found that depression was
common.22 Our findings suggest that transgender men
may represent a high-risk population for postpartum
depression and, although further research is war-
ranted, future recommendations should emphasize
assessment of peripartum depression in this
population.
Nearly half of the transgender men who had not
used testosterone had an unplanned pregnancy, a pro-
portion comparable to that of the U.S. population.23
Comparatively, one fourth of those previously on
testosterone had unplanned pregnancies. By design
this study cannot speak to incidence or prevalence
of unplanned pregnancies among transgender men.
However, given the financial burden24 and risk of
increased morbidity25 from unintended pregnancy
as well as the contraindication of testosterone
use during pregnancy,26,27 these findings suggest
a potential unmet need for contraceptive services
for transgender men.
Limitations to this study include those inherent
with an online, cross-sectional survey, including not
allowing for follow-up clarification from participants,
decreasing responses from those with low literacy or
other barriers to taking an online survey, and self-
reported data raising concern for recall bias. The
limited socioeconomic and racial diversity in respond-
ents reduces immediate generalizability. Lastly, our
eligibility criteria screened for transgender men who
had a successful birth, impeding generalizable to those
who attempt to get pregnant and cannot and those
who do not carry to term. Strengths include the
novelty of reporting transgender men’s pregnancy
experiences, inclusion of those who had socially and
medically transitioned, and the mixed-methods for-
mat that allows insight into experiences.
Through demonstrating that transgender men are
becoming pregnant and having babies, regardless of
prior testosterone use, this preliminary study contrib-
utes data to emerging discussions regarding their
reproductive health experiences. Respondents high-
light the need for health care providers to partner with
this community and develop gender-appropriate re-
sources and support. Simple but meaningful steps for
health care providers include establishing rapport by
using patients’ preferred names and pronouns, vali-
dating gender identity, and reflecting their individual
relationships to their pregnancies. Counseling with
transgender men should include discussions of repro-
ductive goals, including fertility desires, and the role
of contraception. We also suggest all health care
providers discuss fertility preservation options with
patients before initiating testosterone use in accor-
dance with international standards of care.26,27 More
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clinical and investigational work is needed to under-
stand the physical and emotional needs of transgender
men during pregnancy and birth so that health care
providers may partner with this underserved commu-
nity to improve care. As we respond to calls for
increased access to reproductive health care for trans-
gender men, we must ensure that we can provide
evidence-based, comprehensive services befitting
their unique needs and concerns.2
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